摘要
本实验对７０例卵巢浆液癌、１０例交界性癌、２０例卵巢浆液瘤中ＥＧＦＲ（表皮生长因子受体）、ｎｅｕ癌基因、ＰＣＮＡ（增殖细胞核抗原）表达进行研究，观察其在卵巢癌、交界性肿瘤、良性瘤的表达率，并采用半定量的ＡＢＣ免疫组化方法研究不同强度表达与病理分化、临床分期、预后的关系，得到初步结果。ＥＧＦＲ在浆液癌表达５８．５％，交界瘤５０％，浆液瘤５％，其表达率与预后呈负相关，与病理分化、临床分期无明显相关性。ｎｅｕ在卵巢浆液癌中表达４５．７％，交界瘤２０％，浆液瘤０，其阳性表达率及表达强度与预后和病理分化有关。ＰＣＮＡ在浆液癌中表达４７％，交界瘤中３０％，良性瘤１０％，其表达强度与预后和病理分化有关。本实验表明ＥＧＦＲ、ｎｅｕ、ＰＣＮＡ与卵巢浆液癌预后有相关性，ｎｅｕ、ＰＣＮＡ与病理分化也有一定相关性。可能成为判断病理分化、临床预后的指标。
The expression of EGFR、 neu and PCNA in 70 Patients with ovarian surous cystadenocarcinoma was observed with immunohistochemical technique in this study. The relationship between the expression and clinical feature including various pathological grades, clinical stages and prognosis was studied. The results showed that in these 70 patients EGFR was positive in 41 (58. 0% ), neu was positive in 32 (45. 7% ), PCNA was positive in 33 (47% ). EGFR、 neu and PCNA expression was significantly correlated to the pathological grade and clinical prognosis.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1996年第6期335-337,共3页
Cancer Research on Prevention and Treatment
基金
卫生部人才基金
